Bosutinib treatment for Philadelphia chromosome-positive leukemias

Future Oncol. 2014 Feb;10(2):179-85. doi: 10.2217/fon.13.268.

Abstract

The SRC-ABL inhibitor bosutinib is one of the five tyrosine kinase inhibitors currently approved for the treatment of Philadelphia chromosome-positive leukemias. Bosutinib has shown activity against all phases of resistant chronic myeloid leukemia that do not harbor the T315I or V299L ABL kinase domain mutations. Bosutinib is overall well tolerated; transient diarrhea is the most common side effect. This article summarizes the pharmacokinetics, pharmacodynamics, safety and efficacy of bosutinib for the treatment of Philadelphia chromosome-positive leukemias.

MeSH terms

  • Aniline Compounds / adverse effects
  • Aniline Compounds / chemistry
  • Aniline Compounds / pharmacology
  • Aniline Compounds / therapeutic use*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Drug Approval / legislation & jurisprudence
  • Humans
  • Leukemia / drug therapy*
  • Leukemia / genetics*
  • Leukemia / pathology
  • Neoplasm Staging
  • Nitriles / adverse effects
  • Nitriles / chemistry
  • Nitriles / pharmacology
  • Nitriles / therapeutic use*
  • Philadelphia Chromosome*
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / chemistry
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use*
  • Quinolines / adverse effects
  • Quinolines / chemistry
  • Quinolines / pharmacology
  • Quinolines / therapeutic use*
  • Treatment Outcome

Substances

  • Aniline Compounds
  • Antineoplastic Agents
  • Nitriles
  • Protein Kinase Inhibitors
  • Quinolines
  • bosutinib